Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil

Latin American Cooperative Oncology Group33 enrolled

Overview

Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with unresectable stage III NSCLC who completed a platinum-based chemotherapy concurrently or sequentially with radiation therapy without evidence of disease progression 2. Patients who have participated in the Durvalumab EAP in Brazil and have received at least one dose of Durvalumab in the EAP..

Locations (4)

Núcleo de Oncologia da Bahia S.A

Salvador, Estado de Bahia, Brazil

Instituto Mário Penna

Belo Horizonte, Minas Gerais, Brazil

BP - A Beneficência Portuguesa de São Paulo

São Paulo, Brazil

Sociedade Beneficente de Senhoras Hospital Sírio-Libanês

São Paulo, Brazil

Outcomes

Primary Outcomes

Describe real world data on PFS of patients treated with Durvalumab in stage III NSCLC in the EAP in Brazil

Time frame: June of 2018

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.